370 related articles for article (PubMed ID: 16770292)
21. [Use of iumeks in the combined therapy of parkinsonism patients ].
Man'kovskiÄ NB; Karaban' IN; Mialovitskaia EA
Vrach Delo; 1987 Aug; (8):100-2. PubMed ID: 3120415
[No Abstract] [Full Text] [Related]
22. Selegiline's neuroprotective capacity revisited.
Riederer P; Lachenmayer L
J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
[No Abstract] [Full Text] [Related]
23. Deprenyl and levodopa and Parkinson's disease progression.
Fowler JS; Fazzini E; Volkow ND
Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
[No Abstract] [Full Text] [Related]
24. Selegiline transdermal system: a novel treatment option for major depressive disorder.
Nandagopal JJ; DelBello MP
Expert Opin Pharmacother; 2009 Jul; 10(10):1665-73. PubMed ID: 19527191
[TBL] [Abstract][Full Text] [Related]
25. Selegiline transdermal system: in the treatment of major depressive disorder.
Frampton JE; Plosker GL
Drugs; 2007; 67(2):257-65; discussion 266-7. PubMed ID: 17284087
[TBL] [Abstract][Full Text] [Related]
26. The fabulous neuroprotection of selegiline: memoir and prospectus.
Landau WM
J Child Neurol; 2010 Oct; 25(10):1302-4. PubMed ID: 20940135
[No Abstract] [Full Text] [Related]
27. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
Ben-Shlomo Y; Lees A;
Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425
[No Abstract] [Full Text] [Related]
28. Deprenyl in Parkinson's disease.
Korczyn AD; Nisipeanu P
Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
[No Abstract] [Full Text] [Related]
29. Transdermal selegiline in patients receiving electroconvulsive therapy.
Horn PJ; Reti I; Jayaram G
Psychosomatics; 2010; 51(2):176-8. PubMed ID: 20332294
[TBL] [Abstract][Full Text] [Related]
30. Selegiline HC1: Selective MAO-type B inhibitor.
Koller WC; Giron LT
Neurology; 1990 Oct; 40(10 Suppl 3):suppl 58-60. PubMed ID: 2120616
[No Abstract] [Full Text] [Related]
31. Future therapies for Parkinson's disease.
Hauser RA; Lyons KE
Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
[No Abstract] [Full Text] [Related]
32. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
Dubois B; Montastruc JL
Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
[No Abstract] [Full Text] [Related]
33. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
Olanow CW; Mytilineou C; Tatton W
Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
[No Abstract] [Full Text] [Related]
34. Placebo response in Parkinson trials using patient diaries: sites do matter.
Ondo WG
Clin Neuropharmacol; 2007; 30(5):301-4. PubMed ID: 17909309
[No Abstract] [Full Text] [Related]
35. Parkinson's disease.
Imke S
Adv Nurse Pract; 1998 Jan; 6(1):24-8. PubMed ID: 9495941
[No Abstract] [Full Text] [Related]
36. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S
Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874
[TBL] [Abstract][Full Text] [Related]
37. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
Youdim MB; Riederer PF
Neurology; 2004 Oct; 63(7 Suppl 2):S32-5. PubMed ID: 15477584
[No Abstract] [Full Text] [Related]
38. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Jost WH; Friede M; Schnitker J
Eur Rev Med Pharmacol Sci; 2014 Nov; 18(22):3349. PubMed ID: 25491607
[No Abstract] [Full Text] [Related]
39. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS
J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821
[TBL] [Abstract][Full Text] [Related]
40. Selegiline transdermal system Somerset.
Mahmood I
Curr Opin Investig Drugs; 2002 Aug; 3(8):1230-3. PubMed ID: 12211421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]